Cargando…
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
The impressive successes of immune checkpoint blockade antibodies to treat various types of cancer are limited to minor subsets of patients. Combination therapy strategies, including with chemotherapy, are being explored to possibly improve the efficacy of immunotherapies. Here we report results reg...
Autores principales: | Khan, Kabir A., Ponce de Léon, José L., Benguigui, Madeleine, Xu, Ping, Chow, Annabelle, Cruz-Muñoz, William, Man, Shan, Shaked, Yuval, Kerbel, Robert S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371860/ https://www.ncbi.nlm.nih.gov/pubmed/32704531 http://dx.doi.org/10.1038/s41523-020-0171-1 |
Ejemplares similares
-
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
por: Muñoz, Raquel, et al.
Publicado: (2019) -
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
por: Hackl, Christina, et al.
Publicado: (2013) -
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020) -
Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012) -
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
por: Reguera-Nuñez, Elaine, et al.
Publicado: (2019)